Company Overview - Hologic, Inc. is based in Marlborough, Massachusetts and specializes in developing, manufacturing, and supplying diagnostic products, imaging systems, and surgical products for women's health, focusing on early detection and treatment globally [1] - The company has a market capitalization of $16.7 billion, categorizing it as a large-cap stock within the medical instruments and supplies industry [2] Stock Performance - Hologic's stock reached a 52-week high of $76.29 on December 12, 2024, and is currently trading 1.9% below this peak [3] - Over the past three months, Hologic's stock has increased by 12.7%, outperforming the Nasdaq Composite's 7% gains during the same period [3] - Year-to-date, Hologic's stock prices have gained 3.8%, but have decreased by 93 basis points over the past 52 weeks, significantly lagging behind the Nasdaq's 22.2% surge in 2025 and 17.8% returns over the past year [4] Financial Performance - Following the release of better-than-expected Q3 results on November 3, Hologic's stock saw a marginal uptick [5] - The company reported a 6.2% year-over-year growth in overall topline revenue, reaching $1.1 billion, driven by a 5.2% increase in US revenues and a 9.4% surge in international revenues, exceeding market expectations by 1.5% [5] - Despite facing challenges with gross margins due to product mix and increased tariff expenses, Hologic's non-GAAP operating margins improved by 120 basis points year-over-year to 31.2% [6] - The company's non-GAAP EPS rose by 11.9% year-over-year to $1.13, surpassing consensus estimates by 2.7% [6] Competitive Position - Hologic has outperformed its peer, Align Technology, Inc., which experienced a 21.4% decline year-to-date and a 31.6% plunge over the past 52 weeks [7]